The Scan, the Needle, or the Knife? National Trends in Diagnosing Stage I Lung Cancer.
The Scan, the Needle, or the Knife? National Trends in Diagnosing Stage I Lung Cancer.
- 2022
CONCLUSIONS: Diagnostic SB to confirm early-stage NSCLC was associated with younger age, greater travel distance, and shorter time to treatment in comparison with other modalities. Black race and non-private insurance were less likely to be associated with SB. METHODS: The National Cancer Database was queried for all patients with stage I NSCLC from 2004 to 2015. Four diagnostic modalities were identified, including clinical radiography alone (CRA), bronchial cytology (BC), procedural biopsy (PB), and surgical biopsy (SB). A multivariable multinomial logistic regression was used to assess associations of patient demographics, cancer characteristics, and facility characteristics with these modalities. OBJECTIVE: Indeterminate lung nodules have been increasingly discovered since the expansion of lung cancer screening programs. The diagnostic approach for suspicious nodules varies based on institutional resources and preferences. The aim of this study is to analyze factors associated with diagnostic modalities used for early-stage non-small cell lung cancer (NSCLC). RESULTS: Of 250,614 patients, 4,233 (1.7%) had CRA, 5,226 (2.1%) had BC, 147,621 (59.9%) had PB, and 93,534 (37.3%) had SB. Older patients were more likely to receive CRA (adjusted odds ratio [ORadj] = 5.3) and less likely to receive SB (ORadj = 0.73). Black patients were less likely to receive SB (ORadj = 0.83) and more likely to receive BC (ORadj = 1.31). Private insurance was associated with SB (ORadj = 1.11), whereas Medicaid was associated with BC (ORadj = 1.21). Patients more than 50 miles from the facility were more likely to undergo SB (ORadj = 1.25 vs PB; ORadj = 1.30 vs CRA; ORadj = 1.38 vs BC). Patients receiving SB had shorter days from diagnosis to treatment (23.0 vs 53.5 to 64.7 for other modalities, P < 0.001).
English
1556-9845
10.1177/15569845221140399 [doi]
*Carcinoma, Non-Small-Cell Lung
*Lung Neoplasms
Carcinoma, Non-Small-Cell Lung/di [Diagnosis]
Carcinoma, Non-Small-Cell Lung/ep [Epidemiology]
Carcinoma, Non-Small-Cell Lung/su [Surgery]
Early Detection of Cancer
Humans
Lung Neoplasms/di [Diagnosis]
Lung Neoplasms/ep [Epidemiology]
Lung Neoplasms/pa [Pathology]
United States/ep [Epidemiology]
MedStar Washington Hospital Center
Surgery/Thoracic Surgery
Journal Article
CONCLUSIONS: Diagnostic SB to confirm early-stage NSCLC was associated with younger age, greater travel distance, and shorter time to treatment in comparison with other modalities. Black race and non-private insurance were less likely to be associated with SB. METHODS: The National Cancer Database was queried for all patients with stage I NSCLC from 2004 to 2015. Four diagnostic modalities were identified, including clinical radiography alone (CRA), bronchial cytology (BC), procedural biopsy (PB), and surgical biopsy (SB). A multivariable multinomial logistic regression was used to assess associations of patient demographics, cancer characteristics, and facility characteristics with these modalities. OBJECTIVE: Indeterminate lung nodules have been increasingly discovered since the expansion of lung cancer screening programs. The diagnostic approach for suspicious nodules varies based on institutional resources and preferences. The aim of this study is to analyze factors associated with diagnostic modalities used for early-stage non-small cell lung cancer (NSCLC). RESULTS: Of 250,614 patients, 4,233 (1.7%) had CRA, 5,226 (2.1%) had BC, 147,621 (59.9%) had PB, and 93,534 (37.3%) had SB. Older patients were more likely to receive CRA (adjusted odds ratio [ORadj] = 5.3) and less likely to receive SB (ORadj = 0.73). Black patients were less likely to receive SB (ORadj = 0.83) and more likely to receive BC (ORadj = 1.31). Private insurance was associated with SB (ORadj = 1.11), whereas Medicaid was associated with BC (ORadj = 1.21). Patients more than 50 miles from the facility were more likely to undergo SB (ORadj = 1.25 vs PB; ORadj = 1.30 vs CRA; ORadj = 1.38 vs BC). Patients receiving SB had shorter days from diagnosis to treatment (23.0 vs 53.5 to 64.7 for other modalities, P < 0.001).
English
1556-9845
10.1177/15569845221140399 [doi]
*Carcinoma, Non-Small-Cell Lung
*Lung Neoplasms
Carcinoma, Non-Small-Cell Lung/di [Diagnosis]
Carcinoma, Non-Small-Cell Lung/ep [Epidemiology]
Carcinoma, Non-Small-Cell Lung/su [Surgery]
Early Detection of Cancer
Humans
Lung Neoplasms/di [Diagnosis]
Lung Neoplasms/ep [Epidemiology]
Lung Neoplasms/pa [Pathology]
United States/ep [Epidemiology]
MedStar Washington Hospital Center
Surgery/Thoracic Surgery
Journal Article